Monitor for any subsequent definitive agreements or partnership announcements involving IN01; without financial terms, this filing has no immediate revenue or cost impact.
Price Chart
Executive Summary
BIOT announced a non-exclusive appointment by CelSiege Biosciences as its authorized business development representative in Japan and China for IN01, a clinical-stage cancer immunotherapy targeting EGF. This is a low-value, non-binding agreement with no upfront payment or guaranteed revenue, and any definitive transaction remains subject to separate negotiations.
Key Facts
- CelSiege appointed BIOT as non-exclusive authorized representative for IN01 in Japan and China under a Letter of Authorisation dated September 18, 2026.
- IN01 is a clinical-stage therapeutic cancer vaccine targeting EGF, with lead indication in squamous non-small cell lung cancer.
- No upfront payment, milestone, or revenue terms are disclosed; any definitive transaction requires separate negotiations and definitive agreements.
- BIOT's core business is diversified healthcare and biotechnology across beauty, wellness, and regenerative medicine — not clinical-stage oncology development.
Financial Impact
No financial terms disclosed; non-exclusive appointment with no guaranteed revenue or milestone payments.
Risk Factors
- Non-exclusive appointment means CelSiege can appoint other representatives, limiting BIOT's potential upside.
- IN01 is clinical-stage and unapproved; any future revenue is highly uncertain and years away.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-112508 |
| Document: tm2626707d1_6k.htm | 0001104659-26-112508 |
| Document: 0001104659-26-112508-index-headers.html | 0001104659-26-112508 |
| Document: 0001104659-26-112508-index.html | 0001104659-26-112508 |
| Document: 0001104659-26-112508.txt | 0001104659-26-112508 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 11d ago | 6-K | $0.2300 | awaiting T+20 | — | $0.2007 (−12.74%) |
Oct 1, 2026 26d ago | 6-K | $0.3533 | awaiting T+20 | — | $0.2007 (−43.19%) |
Sep 15, 2026 6w ago | 6-K | $0.3700 $0.3602 | ▲ +2.65% | ▲ +5.63% | $0.2007 (+45.76%) |
Aug 10, 2026 11w ago | 6-K | $0.4019 $0.3863 | ▼ −3.88% | ▼ −2.97% | $0.2007 (−50.06%) |
Jul 30, 2026 12w ago | 6-K | $0.4990 $0.4470 | ▼ −10.42% | ▼ −14.39% | $0.2007 (−59.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers